(Q37523946)

20 August 2017

1 reference

title

Naltrexone for the treatment of obesity: review and update (English)

1 reference

20 August 2017

0 references

0 references

Michael William Lee

1

1 reference

20 August 2017

Ken Fujioka

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

Expert Opinion on Pharmacotherapy

20 August 2017

published in

1 reference

20 August 2017

volume

10

1 reference

20 August 2017

issue

11

1 reference

20 August 2017

page(s)

1841-1845

1 reference

Suppression of appetitive behavior in the rat by naloxone: Lack of effect of prior morphine dependence

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Amphetamine- and morphine-induced feeding: evidence for involvement of reward mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Activation of hypothalamic β-endorphin pools by reward induced by highly palatable food

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Effects of taste stimulation on beta-endorphin levels in rat cerebrospinal fluid and plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Opioid peptides and the control of human ingestive behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Taste responses and preferences for sweet high-fat foods: Evidence for opioid involvement☆

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Hyperendorphinemia in obesity and relationships to affective state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Hyperendorphinemia in obesity is not related to the affective state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Antagonists, inverse agonists, and protagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Anorexic effects of naltrexone in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Selective effects of naltrexone on food pleasantness and intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetizer effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Effect of naltrexone on food intake, hunger, and satiety in obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Effects of long-term therapy with naltrexone on body weight in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

To eat or not to eat - how the gut talks to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Anatomy and regulation of the central melanocortin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Rational design of a combination medication for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

Pharmacologic treatment options for obesity: current and potential medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903048959

10.1517/14656560903048959

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference